Abstract
Mismanagement of bacterial infection therapies has undermined the reliability and efficacy of antibiotic treatments, producing a profound crisis of the antibiotic drug market. It is by now clear that tackling deadly infections demands novel strategies not only based on the mere toxicity of anti-infective compounds. Host-directed therapies have been the first example as novel treatments with alternate success. Nevertheless, recent advances in the human microbiome research have provided evidence that compounds produced by the microbial metabolism, namely postbiotics, can have significant impact on human health. Such compounds target the host-microbe-pathogen interface rescuing biotic and immune unbalances as well as inflammation, thus providing novel therapeutic opportunities. This work discusses critically, through literature review and personal contributions, these novel nonantibiotic treatment strategies for infectious disease management and resistance prevention, which could represent a paradigm change rocking the foundation of current antibiotic therapy tenets.
Funder
Fondazione per la Ricerca sulla Fibrosi Cistica
Reference306 articles.
1. Antimicrobial resistance (AMR)
2. Surveillance for control of antimicrobial resistance
3. Vital signs: Carbapenem-resistant enterobacteriaceae;Jacob;Morb. Mortal. Wkly. Rep.,2013
4. The Future of Antibiotics and Resistance: A Tribute to a Career of Leadership by John Bartlett
5. Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation 2020,2020
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献